Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patient
American Journal of Hematology, 05/15/2012
Clinical Article
Ansell SM et al. – Elevated pretreatment serum IP–10 levels are associated with an increased likelihood of disease relapse and an inferior survival in patients with diffuse large B–cell lymphoma (DLBCL).



